Drugs / fhB7H3.CAR-Ts
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05323201 | Feb 2022 → Feb 2024 overdue | hepatocellular carcinoma | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05211557 | Nov 2021 → Aug 2023 overdue | ovarian cancer | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fhB7H3.CAR-Ts | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05323201 ↗ |
| Action | Deplete | “which are supposed to attack and eliminate B7H3-positive cancer cells” NCT05211557 ↗ |
| Modality | Cell therapy | “fully human scFv-armed B7H3 targeting chimeric antigen receptor T cells (fhB7H3.CAR-Ts)” NCT05211557 ↗ |
| Route | Other | “fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion.” NCT05323201 ↗ |